| Title |
Pharmacoeconomics of the Myeloid Growth Factors
|
|---|---|
| Published in |
PharmacoEconomics, December 2012
|
| DOI | 10.2165/11590130-000000000-00000 |
| Pubmed ID | |
| Authors |
Bradford R. Hirsch, Gary H. Lyman |
| Abstract |
The pharmacoeconomics of the myeloid growth factors (MGFs) is an important topic that has received substantial attention in recent years. The use of the MGFs as primary prophylaxis to prevent febrile neutropenia (FN) has grown considerably over the past decade and professional guidelines regarding their use have broadened the settings in which these agents are indicated. Recent data also suggest a potential role for them in reducing infection-related and all-cause mortality. The cost and effectiveness of these agents will continue to gain visibility as companies pursue approval for biosimilar agents in the US, similar to their recent approval in Europe. |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | 1% |
| Unknown | 67 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 15 | 22% |
| Student > Master | 15 | 22% |
| Student > Bachelor | 6 | 9% |
| Student > Ph. D. Student | 5 | 7% |
| Student > Postgraduate | 5 | 7% |
| Other | 10 | 15% |
| Unknown | 12 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 7 | 10% |
| Economics, Econometrics and Finance | 6 | 9% |
| Nursing and Health Professions | 5 | 7% |
| Biochemistry, Genetics and Molecular Biology | 4 | 6% |
| Other | 10 | 15% |
| Unknown | 12 | 18% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 December 2012.
All research outputs
#22,760,732
of 25,374,917 outputs
Outputs from PharmacoEconomics
#1,930
of 1,992 outputs
Outputs of similar age
#258,628
of 289,102 outputs
Outputs of similar age from PharmacoEconomics
#276
of 280 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,992 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,102 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 280 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.